Bright Minds Biosciences Inc. (DRUG)
Bright Minds Biosciences Inc. (DRUG) tracked by StreetAlpha. It last closed at $26.20 on Nov 2. DRUG reports earnings on Tue, Dec 22, 2026. The average 12-month price target from 3 analysts is $147.33 (+462.3% from the last close), with a high of $150.00 and a low of $145.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on DRUG in the past 90 days. The average target is $147.33, with a high of $150.00 and a low of $145.00, compared with the last close of $26.20.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 15 | Wolfe Research | Initiated | Buy | $150 |
| Aug 19 | HC Wainwright & Co. | Reiterated | Buy | $145 |
| Aug 17 | BTIG | Reiterated | Buy | $147 |
| May 20 | Piper Sandler | Maintained | Buy | $220 |
| Apr 13 | Jefferies | Initiated | Buy | $145 |
Technical Analysis
The stock is 97% below its 20 day and 122% below its 50 day average. It is 178% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 23), oversold. The nearest support is the Pivot at $25.01, and the nearest resistance the Pivot R1 at $31.13.
| RSI (14) | 22.75 | Oversold below 30 | Oversold |
| MACD | -3.01 | Below its signal line | Bearish |
| Stochastic | 48.4 | Middle of its range | Neutral |
| ADX (14) | 25.1 | Trending down | |
| Williams %R | -82.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -570.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −51.3% | Change over 10 sessions | Bearish |
| ATR (14) | $5.82 | Typical daily range, 22.2% of price |
| RSI (14) | 25.46 | Oversold below 30 | Oversold |
| MACD | -7.96 | Below its signal line | Bearish |
| Stochastic | 14.5 | Near the bottom of its range | Oversold |
| ADX (14) | 18.3 | No clear trend | |
| Williams %R | -89.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -243.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −64.0% | Change over 10 sessions | Bearish |
| ATR (14) | $11.01 | Typical daily range, 42.0% of price |
What happened before
See how DRUG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How DRUG has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in DRUG in the last 90 days.
DRUG Institutional Ownership
Hedge fund holdings →- Point72 Asset Management, L.P.+327K sh$23.0M
- Parkman Healthcare Partners LLC+165K sh$11.6M
- Citadel Advisors LLC+67K sh$4.7M
- BlackRock, Inc.+64K sh$4.5M
- Trexquant Investment LP+63K sh$4.4M
- Goldman Sachs Group Inc+59K sh$4.2M
- Perceptive Advisors LLC−378K sh−$27.5M
- Adage Capital Partners Gp, L.l.c.−161K sh−$11.3M
- Cormorant Asset Management, LP−159K sh−$11.2M
- Morgan Stanley−114K sh−$8.0M
- Great Point Partners LLC−110K sh−$7.7M
- Ikarian Capital, LLC−78K sh−$5.5M
- Strs OhioTrimmed−2,400 shOct 30
- Caitong International Asset Management Co., LtdTrimmed−1,180 shOct 29
- State of WyomingSold out−479 shOct 28
- Sterling Capital Management LLCAdded+217 shOct 22
- Pinnacle Wealth Planning Services, Inc.Trimmed−111 shOct 27
- China Universal Asset Management Co., Ltd.Trimmed−100 shOct 28
- Rydar Equities, Inc.New+80 shOct 13
- Farther Finance Advisors, LLCNew+47 shOct 8
From SEC Form 13F filings by funds managing over $100 million, as of Jun 30, 2026. Changes compare each fund with its own Q1 2026 filing. Filings come up to 45 days after the quarter ends. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DRUG is in one of them and how their past DRUG trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered DRUG in an article yet. Here's the latest on the wider market.